Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
203Pb-DOTAM
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
203Pb-DOTAM is a radiopharmaceutical imaging agent developed by Hoffmann-La Roche in collaboration with Orano Med as part of the CEA-PRIT 2.0 pretargeted radioimmunotherapy (PRIT) platform. It functions as a diagnostic and dosimetry surrogate for the therapeutic alpha-emitter 212Pb-DOTAM. The system employs 'SPLIT' (SeParated v-domains LInkage Technology) bispecific antibodies that target Carcinoembryonic Antigen (CEA), which is highly expressed in metastatic colorectal cancer. These antibodies localize to the tumor and subsequently capture the chelated lead-203 (203Pb) via a high-affinity DOTAM-binding site. This approach allows for precise SPECT imaging to visualize tumor uptake and calculate radiation dosimetry prior to the administration of the therapeutic lead-212 (212Pb) counterpart, minimizing off-target toxicity and enhancing the precision of targeted alpha therapy.
- Other names
- Lead-203 DOTAMLead203 DOTAMLead 203 DOTAM203Pb-labeled DOTAM
02
Targets
DOTAM-binding site on the CEA-targeted bispecific antibody
Beyond the preview
Go deeper on 203Pb-DOTAM.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 203Pb-DOTAM.